Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study
- 12 May 2011
- journal article
- research article
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 65 (6) , 679-683
Abstract
Aims: The impact of statins on glucose metabolism and adipokines remains controversial. We compared the effects of rosuvastatin and atorvastatin on glucose homeostasis, insulin sensitivity (IS), adiponectin and leptin levels as well as systemic inflammation in non‐diabetic patients with dyslipidaemia. Methods: Thirty‐six patients were randomly assigned to 10 mg/day of rosuvastatin (n = 18) or 20 mg/day of atorvastatin (n = 18) for 12 weeks. Total cholesterol (TC), low‐density lipoprotein cholesterol (LDL‐C), high‐density lipoprotein cholesterol (HDL‐C), non‐HDL‐C, triglycerides (TG), fasting plasma glucose, insulin, homeostasis model assessment‐insulin resistance (HOMA‐IR), quantitative IS check index (QUICKI), adiponectin, leptin and high‐sensitivity C‐reactive protein (hsCRP) were measured at baseline and after 4 and 12 weeks. Results: Both statins significantly lowered TC, LDL‐C, non‐HDL‐C and TG compared with baseline. Only rosuvastatin caused a significant reduction in insulin and HOMA‐IR levels (−35%, p = 0.005 and −33%, p = 0.011 respectively) and a significant increase in QUICKI (+11%, p = 0.003) at 12 weeks. In terms of adipokines and hsCRP, no difference was observed after 4 and 12 weeks of treatment with either statin. Conclusions: Rosuvastatin compared with atorvastatin resulted in significant improvements in IS indices. No significant changes in adiponectin, leptin or hsCRP levels were observed at 4 and 12 weeks of treatment with either statin.Keywords
This publication has 28 references indexed in Scilit:
- Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetesAtherosclerosis, 2010
- Atorvastatin Causes Insulin Resistance and Increases Ambient Glycemia in Hypercholesterolemic PatientsJACC, 2010
- Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsThe Lancet, 2010
- Comparative Study of Low Doses of Rosuvastatin and Atorvastatin on Lipid and Glycemic Control in Patients with Metabolic Syndrome and HypercholesterolemiaThe Korean Journal of Internal Medicine, 2010
- Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucoseInternational Journal Of Clinical Practice, 2009
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patientsAtherosclerosis, 2008
- HOMA or QUICKI: Is it useful to test the reproducibility of formulas?Diabetes & Metabolism, 2008
- Effect of Atorvastatin (10 mg/day) on Glucose Metabolism in Patients With the Metabolic SyndromeThe American Journal of Cardiology, 2006
- Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemiaEuropean Journal of Clinical Investigation, 2005